| Literature DB >> 34012783 |
Daniel Kazdal1,2, Eugen Rempel1, Cristiano Oliveira1, Michael Allgäuer1, Alexander Harms1, Kerstin Singer3, Elke Kohlwes4, Steffen Ormanns5, Ludger Fink6, Jörg Kriegsmann7, Michael Leichsenring8, Katharina Kriegsmann9, Fabian Stögbauer10, Luca Tavernar1, Jonas Leichsenring1, Anna-Lena Volckmar1, Rémi Longuespée11, Hauke Winter2,12, Martin Eichhorn2,12, Claus Peter Heußel12,13, Felix Herth2,14, Petros Christopoulos2,15, Martin Reck2,16, Thomas Muley2,17, Wilko Weichert10, Jan Budczies1, Michael Thomas2,15, Solange Peters18, Arne Warth1,6, Peter Schirmacher1,19,20, Albrecht Stenzinger1,2, Mark Kriegsmann1,2.
Abstract
BACKGROUND: Targeted genetic profiling of tissue samples is paramount to detect druggable genetic aberrations in patients with non-squamous non-small cell lung cancer (NSCLC). Accurate upfront estimation of tumor cell content (TCC) is a crucial pre-analytical step for reliable testing and to avoid false-negative results. As of now, TCC is usually estimated on hematoxylin-eosin (H&E) stained tissue sections by a pathologist, a methodology that may be prone to substantial intra- and interobserver variability. Here we the investigate suitability of digital pathology for TCC estimation in a clinical setting by evaluating the concordance between semi-automatic and conventional TCC quantification.Entities:
Keywords: Digital pathology; lung adenocarcinoma (lung ADC); molecular pathology; next-generation sequencing (NGS); tumor cell content (TCC)
Year: 2021 PMID: 34012783 PMCID: PMC8107748 DOI: 10.21037/tlcr-20-1168
Source DB: PubMed Journal: Transl Lung Cancer Res ISSN: 2218-6751
Figure 1Study design: TCC of 120 images with an area of 1.5 to 2.0 mm2 of pulmonary adenocarcinoma were determined using the two digital pathology software applications HALO (Indica Labs) and the open source software QuPath as well as by 19 conventional estimators, comprising 7 BP, 7 PT and 5 NP. Fifty images were chosen separately for H&E and TTF-1 IHC, representing each 10 cases of the five histological growth patterns (lepidic, acinar, papillary, solid, micropapillary). In addition, 20 of these images (10 of each staining and 2 of each growth pattern) were duplicated and rotated by 180° in order to evaluate the intraobserver reliability. TCC, tumor cell content; BP, board-certified pathologist; PT, pathologist in training; NP, non-pathologist; H&E, hematoxylin-eosin; TTF-1, thyroid transcription factor 1; IHC, immunohistochemistry.
Figure 2Overview of TCC estimates. The heat map shows the estimated TCC of all H&E and TTF-1 stained display images assessed with the two digital pathology applications (Q: QuPath, H: HALO) and by conventional manual evaluation (participants: 1–19), as well as the average of digital (ØdPat) and conventional (Øconv) estimates of each image. MADs were calculated for digital and conventional estimations separately, and the absolute difference (Diff.) between the average values ØdPat and Øconv. GP: histological growth pattern shown in the respective image. TCC, tumor cell content; H&E, hematoxylin-eosin; TTF-1, thyroid transcription factor 1; IHC, immunohistochemistry; MAD, mean absolute deviation.
Figure 3Inter-rater reliability of the TCC estimations. (A) ICC for the agreement within different estimator groups for H&E and TTF-1 stainings. (B) Scatter plots and ICC for the comparison of average digital and average conventional estimations considering all conventional estimators or subsets of BP, PT or NP for both stainings. ICC, intra-class correlation coefficients; H&E, hematoxylin-eosin; TTF-1, thyroid transcription factor 1; BP, board-certified pathologist; PT, pathologist in training; NP, non-pathologist.
Figure 4Factors influencing TCC estimation—histological growth pattern (A,B,C) and the genuine TCC (D). (A) ICC calculated separately for subsets regarding the predominant histological growth pattern of the tumor section. (B) TCC estimations of the predominant solid tumor sections, x = conv TCC estimates; red line ØdPat. (C) Representative image of error prone section = HE-S5 and corresponding QPath evaluation. (D) Ratio of over- and underestimation (±10%) with regard to the ØdPat TCC of a sample, blue: underestimation, grey: within 10% difference, red: overestimation. TCC, tumor cell content; ICC, intra-class correlation coefficients; H&E, hematoxylin-eosin; TTF-1, thyroid transcription factor 1.
Figure 5Consistency of TCC estimations. (A) Average difference in the re-estimation of the 180° flipped H&E or TTF-1 stainings for the conventional and the digital TCC estimations. (B) Percentage of re-estimations with a respective difference of 0%, ≤5%, ≤10% and >10% assessed by BP, PT, NP as well as by using the QuPath and HALO software. TCC, tumor cell content; H&E, hematoxylin-eosin; TTF-1, thyroid transcription factor 1; BP, board-certified pathologist; PT, pathologist in training; NP, non-pathologist.
Figure 6Overview of factors improving or impairing the TCC estimation. TCC, tumor cell content; H&E, hematoxylin-eosin; TTF-1, thyroid transcription factor 1.